{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:16:01Z","timestamp":1761894961017},"reference-count":55,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2009,10,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To determine overall response rate (ORR), time to progression (TTP), and duration of response (DOR) with twice-weekly\/weekly bortezomib plus rituximab, and evaluate safety\/tolerability, in patients with relapsed or refractory CD20<jats:sup>+<\/jats:sup> follicular lymphoma (FL) or marginal-zone lymphoma. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients were randomly assigned (minimization method) to bortezomib 1.3 mg\/m<jats:sup>2<\/jats:sup> twice weekly (days 1, 4, 8, and 11; 21-day cycle, five cycles; arm A) or bortezomib 1.6 mg\/m<jats:sup>2<\/jats:sup> weekly (days 1, 8, 15, and 22; 35-day cycle, three cycles; arm B) plus rituximab 375 mg\/m<jats:sup>2<\/jats:sup> weekly for 4 weeks (both arms). Response\/progression was determined by International Workshop Response Criteria using oncologist\/radiologist-adjudicated data from independent radiology review and investigator assessment. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Eighty-one patients (arm A, n = 41; arm B, n = 40) were enrolled. Dose-intensity was higher in arm A; mean total bortezomib received was similar between arms (18.5 and 17.1 mg\/m<jats:sup>2<\/jats:sup>). In arm A, ORR was 49% (14% complete response [CR]\/CR unconfirmed [CRu]), median TTP was 7.0 months, and median DOR was not reached. In arm B, ORR was 43% (10% CR\/CRu), and median TTP\/DOR were 10.0\/9.3 months. The weekly combination regimen seemed better tolerated. Grade 3 or worse adverse events seemed more common in arm A (54%) versus arm B (35%), including thrombocytopenia (10% v 0%) and peripheral neuropathy (10% v 5%), but diarrhea seemed less frequent (7% v 15%). No grade 4 toxicities were reported in arm B. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Both bortezomib plus rituximab regimens seem feasible in relapsed or refractory indolent lymphomas. The more convenient weekly combination regimen is being compared with single-agent rituximab in an ongoing phase III study in relapsed FL. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2008.17.7980","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T01:32:00Z","timestamp":1253583120000},"page":"5023-5030","source":"Crossref","is-referenced-by-count":75,"title":["Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma"],"prefix":"10.1200","volume":"27","author":[{"given":"Sven","family":"de Vos","sequence":"first","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Goy","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaker R.","family":"Dakhil","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor N.","family":"Saleh","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Belt","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Knapp","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lowell","family":"Hart","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipti","family":"Patel-Donnelly","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Glenn","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie A.","family":"Gregory","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Holladay","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony L.","family":"Boral","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; Hackensack University Medical Center, Hackensack, NJ; Cancer Center of Kansas, Wichita, KS; Georgia Cancer Specialists, Atlanta, GA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Kansas City Cancer Care, Kansas City, MO; Winship Cancer Institute, Atlanta, GA; Mid Ohio Oncology\/Hematology Inc, Columbus, OH; Florida Cancer Specialists, Fort Myers, FL;..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207843"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/CA.2007.0010"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi098"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2004.02.007"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.307"},{"key":"B8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11901-005-0025-1","volume":"4","author":"Maloney DG","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06378.x"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske C","year":"2006","journal-title":"Blood"},{"key":"B15","first-page":"CD003805","volume":"4","author":"Schulz H","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","first-page":"104","volume":"91","author":"Buske C","year":"2006","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh002"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.018"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1851"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"B22","first-page":"811","volume":"88","author":"Cohen Y","year":"2003","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200620010-00002"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"B26","doi-asserted-by":"crossref","first-page":"v66","DOI":"10.1093\/annonc\/mdi809","volume":"16","author":"O'Connor OA","year":"2005","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6789"},{"key":"B29","first-page":"453s","volume":"25","author":"O'Connor O","year":"2007","journal-title":"J Clin Oncol"},{"key":"B30","first-page":"iv191","volume":"19","author":"Conconi A","year":"2008","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1361"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.030"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0944-5"},{"key":"B34","first-page":"1136","volume":"9","author":"Ma MH","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"crossref","first-page":"448a","DOI":"10.1182\/blood.V110.11.448.448","volume":"110","author":"Ailawadhi S","year":"2007","journal-title":"Blood"},{"key":"B36","first-page":"903a","volume":"102","author":"Hernandez-Ilizaliturri FJ","year":"2003","journal-title":"Blood"},{"key":"B37","first-page":"126","volume":"45","author":"De Vos S","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.03.005"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.09.004"},{"key":"B40","unstructured":"Millennium Pharmaceuticals Inc: VELCADE (bortezomib) for Injection: Prescribing information Cambridge, MA June 2008, Rev 9, 2008"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1978.124"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.106"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2046"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23606"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7779"},{"key":"B53","doi-asserted-by":"crossref","first-page":"208a","DOI":"10.1182\/blood.V108.11.694.694","volume":"108","author":"De Vos S","year":"2006","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.5358"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.8512"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.17.7980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:23:41Z","timestamp":1653521021000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.17.7980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,20]]},"references-count":55,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2009,10,20]]}},"alternative-id":["10.1200\/JCO.2008.17.7980"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.17.7980","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,20]]}}}